Pharmacokinetics and Pharmacodynamics of Intravenous Administration of Pegylated Interferon-2a in Patients With Chronic Hepatitis C and Previous Non-response to Standard Combination Therapy With Pegylated Interferon and Ribavirin (Intervention Study)

Trial Profile

Pharmacokinetics and Pharmacodynamics of Intravenous Administration of Pegylated Interferon-2a in Patients With Chronic Hepatitis C and Previous Non-response to Standard Combination Therapy With Pegylated Interferon and Ribavirin (Intervention Study)

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2a (Primary)
  • Indications Hepatitis C
  • Focus Pharmacodynamics; Proof of concept
  • Acronyms IVAN
  • Sponsors Roche
  • Most Recent Events

    • 21 May 2012 Actual patient number changed from 17 to 31 as reported by ClinicalTrials.gov.
    • 21 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Apr 2012 Actual end date Apr 2012 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top